Table 1.

Effect of uPA, tPA and Plg single deficiencies, uPA;tPA double-deficiency and galardin treatment on wound healing time

Group	Genotype	Number of backcrossings	Treatment	Number of mice	Mean healing time (days)	s.d.	P-value
1	Wild-type	16	None	30	16.9	3.2
2	uPA−/−; tPA+/+	16	None	13	18.2	2.7	2 versus 1 NSa
3	uPA+/+; tPA−/−	16	None	17	17.6	2.8	3 versus 1 NSa
4	uPA−/−; tPA−/−	16	None	13	31.2	11.3	4 versus 1 0.0006
5	Wild-type	21	None	24	16.8	2.2
6	Plg−/−	21	None	20	42.9	15.6	6 versus 5 0.0001; 6 versus 4 0.03
7	Wild-type	16	Mock	16	17.0	3.7
8	Wild-type	16	Galardinb	10	22.3	5.5	8 versus 7 0.008
9	uPA−/−; tPA−/−	16	Mock	13	30.2	10.0	9 versus 7 0.0004
10	uPA−/−; tPA−/−	16	Galardinb	7	45.9	6.9	10 versus 9 0.002
11	Wild-type	21	Mock	15	19.0	2.9
12	Wild-type	21	Galardinb	15	24.9	3.8	12 versus 11 0.0001
13	Plg−/−	21	Mock	14	50.9	19.3	13 versus 11 0.0001; 13 versus 9 0.002
14	Plg−/−	21	Galardinb	12	>70 daysc		14 versus 13 0.0001; 14 versus 10 0.0001
Not significant (P>0.05).
100 mg/kg daily.
No wounds healed at end of galardin treatment.
Abbreviations: Plg, plasminogen; tPA, tissue-type plasminogen activator; uPA, urokinase-type plasminogen activator.